Thrasos
Montréal
About Thrasos
Thrasos is a bio-therapeutics company focused on the discovery and development of targeted therapies for the prevention and treatment of severe organ failure, with a principle focus on kidney disease. The Company's lead therapeutic program, THR-184, is focused on the prevention and treatment of acute kidney injury (AKI). The Company also has a preclinical development program for treating chronic kidney disease (CKD).
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $56.0M
- Funding stage: Late Stage Venture
- Last round: Series D (Mar 2015)
- Website: thrasos.com
- Phone: 514-940-2714
Industries & Categories
Biotechnology, Health Care, Medical Device, Therapeutics
Canonical: https://fsome.com/organization/thrasos-2653244 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.